Bladder Exstrophy

BALTIMORE, Aug. 1, 2023 /PRNewswire/ -- The Urology Care Foundation, the world's leading nonprofit urological health foundation and official foundation of the American Urological Association, is pleased to announce the 2023 Urology Care Foundation Humanitarian Grant recipients. This year marks the most diverse recipients to date, with a majority of the seven grants being led by urologists from underrepresented in medicine backgrounds. As one of the world's largest urology-specific humanitarian-focused grant programs, the Urology Care Foundation Humanitarian Grants aids the efforts of urologists and projects providing patient care and education in underserved areas, either within the United States or worldwide. Congratulations to this year's grant recipients: Lee Richter, MD – Dr. Richter is associate professor of urology, obstetrics and gynecology at Georgetown University School of Medicine. She also is a member of the International Organization for Women and Development Board where she travels each year to Rwanda for a 2-week medical mission evaluating and operating to repair fistula. Suzette Sutherland, MD – Dr. Sutherland is an associate professor of urology at the University of Washington and travels regularly to Dakar, Senegal, where she provides education and training in women's pelvic and genitourinary health. Her Fall 2023 trip with IVUmed will be dedicated to the evaluation of stress urinary incontinence with an emphasis on minimally invasive and low-risk surgical treatment options. Rajiv K. Singal, MD, FRCSC – Dr. Singal is the surgeon-in-chief at Michael Garron Hospital in Toronto, associate professor in the department of surgery at the University of Toronto and leads trips to the Zomba Central Hospital in Malawi. Thanks to his help with the Malawi Medical Council and the College of Surgeons of Eastern Central and Southern Africa (COSECSA), a Malawian urologist has been trained to help provide a long-term sustainable solution to the lack of urologic care in the country. Dana Weiss, MD – Dr. Weiss is a pediatric urology specialist at The Children's Hospital of Philadelphia and travels each year to the Civil Hospital Amdavad in Ahmedabad, Gujarat, India. Her work and the project that is going into its 16th year, have provided direct care to one of the largest groups of patients in the world affected by bladder exstrophy. Samit Sunny Roy, MD, MSPH – Dr. Roy is a resident at the University of Tennessee under the mentorship of Dr. Amar Singh. Dr. Roy will visit the Sadbhavna Trust Hospital Trust Hospital, Kalsar, Bhavnagar, in Mahua, Gujarat, India, providing training in routine and complex urologic surgery and post operative care. Kymora Scotland, MD – Dr. Scotland is an assistant professor of urology, director of endourology research and associate director of the Endourology Fellowship Program at the University of California, Los Angeles. Dr. Scotland will partner with Gold Standard Urology to provide urologic screening events that bring the medical community directly to patients in south Los Angeles, with a focus on prostate cancer, incontinence, nephrolithiasis and erectile dysfunction. Matthew T. Smith, Jr., MD – Dr. Smith is an assistant professor and director of resident education at SUNY Downstate University and is committed to increasing health literacy among African American men through accessible, relevant and digestible information delivered in the centers of the Black community in New York City. His project involves giving health education lectures to Black men in public community centers. "We continue to be extraordinarily pleased by all the outstanding applicants we received for these grants. The continued and growing interest demonstrates the importance of humanitarian work to our members," said Harris M. Nagler, MD, president of the Urology Care Foundation. "The projects proposed will not only make a difference to the populations aided but will hopefully inspire others to continue these efforts." Grants were made possible through funds from the American Urological Association Humanitarian Endowment, the Amerson Family Humanitarian Endowment, the Richard J. Fox Foundation Humanitarian Endowment, the Nathirmal N. Lalchandani Humanitarian Endowment, the Endourological Society Raju and Ginny Thomas Humanitarian Endowment, the Indian American Urological Association Humanitarian Endowment and from an Exelixis grant, and other contributors. Learn more about the Urology Care Foundation Humanitarian Grant Program and the work of the 2023 grant recipients: About the Urology Care Foundation: The Urology Care Foundation is the world's leading nonprofit urological health foundation, and the official foundation of the American Urological Association. Collaborating with physicians, researchers, patients and the public, the Foundation supports and improves urologic clinical care by funding research, developing patient education and pursuing philanthropic support. To learn more about the Urology Care Foundation and its programs visit: . About the American Urological Association: Founded in 1902 and headquartered near Baltimore, Maryland, the American Urological Association is a leading advocate for the specialty of urology, and has more than 23,000 members throughout the world. The AUA is a premier urologic association, providing invaluable support to the urologic community as it pursues its mission of fostering the highest standards of urologic care through education, research and the formulation of health care policy. Contact: Corey Del Bianco, Corporate Communications & Media Relations Manager 410-689-4033 [email protected] SOURCE American Urological Association and Urology Care Foundation

Q-Med AB and Medy-Tox Inc., a pharmaceuticals company based in South Korea, have together decided to terminate the collaboration that the parties entered into during 2007. The collaboration comprised the development and commercialization of new products based on botulium toxin and potential for Q-Med to distribute Medy-Tox’s existing botulinum toxin type A product. The parties have both signed a separation agreement, amongst other things, where they agree to a financial settlement which entails Medy-Tox repaying the majority of the loan that Q-Med has given the company up until the present date. Further details concerning the repayment will not be made public, however. The parties’ original agreement included Q-Med giving Medy-Tox a loan of up to 3 MUSD for the adaptation of facilities and manufacturing processes, and paying up to 8 MUSD on condition that certain commercial objectives were achieved. Q-Med still aims to continue work on the development and commercialization of products within the botulinum toxin area. Queries should be addressed to: Alexander Kotsinas, Vice president and CFO Tel: +46 (0)73 500 11 11 Madelene Sandgren, Director Investor Relations and Corporate Communications Tel: + 46 (0)70 974 90 15 Q-Med AB (publ), Seminariegatan 21, SE-752 28 Uppsala, Sweden. Corporate identity number 556258-6882. Tel: +46(0)18-474 90 00. Fax: +46(0)18-474 90 01. E-mail: info@q-med.com. Web: In USA, Q-Med AB’s affiliate is the wholly-owned subsidiary Q-Med Scandinavia, Inc. Q-Med AB is a rapidly growing and profitable biotechnology/medical device company. The company develops, manufactures, markets, and sells primarily medical implants. The majority of the products are based on the company's patented technology, NASHA™, for the production of stabilized non-animal hyaluronic acid. The product portfolio today contains: Restylane® for filling lines and folds, contouring and creating volume in the face, Macrolane™ for body contouring, Durolane™ for the treatment of osteoarthritis of the hip and knee joints, Deflux® for the treatment of vesicoureteral reflux, VUR, (a malformation of the urinary bladder) in children, and Solesta™ for the treatment of fecal incontinence. Sales are made through the company's own subsidiaries or distributors in over 70 countries. Q Med today has just over 700 coworkers, with close to 500 at the company's head office and production facility in Uppsala, Sweden. Q-Med AB is listed in the Mid Cap segment of the OMX Nordic Exchange in Stockholm. This information was brought to you by Cision Contact: Q-Med AB Alexander Kotsinas, Vice president and CFO Tel: +46 (0)73 500 11 11 or Madelene Sandgren, Director Investor Relations and Corporate Communications Tel: + 46 (0)70 974 90 15 Source: Q-Med